In particular, a 28-year-old patient with stage IV pancreatic ductal adenocarcinoma with a confirmed FGFR2 rearrangement treated with erdafitinib, an orally administered tyrosine kinase inhibitor of FGFR1–4, had a favorable response to this treatment for more than 12 months, with an improvement of previous pancreatic-ductal-adenocarcinoma-related weight loss and a resolution of ascites and hypercalcemia [62]. Here, FGFR1 is linked to pancreatic ductal adenocarcinoma.